(0.69%) 5 081.25 points
(0.45%) 38 240 points
(0.92%) 17 599 points
(0.54%) $79.43
(1.71%) $1.965
(-0.13%) $2 307.90
(-1.10%) $26.46
(0.43%) $959.00
(0.13%) $0.934
(0.46%) $11.08
(0.10%) $0.799
(-1.55%) $91.81
Live Chart Being Loaded With Signals
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight...
Stats | |
---|---|
本日の出来高 | 72 838.00 |
平均出来高 | 333 607 |
時価総額 | 29.67M |
EPS | €0 ( 2024-04-08 ) |
次の収益日 | ( €0 ) 2024-05-15 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.590 |
ATR14 | €0.00400 (0.63%) |
ボリューム 相関
Poxel SA 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Poxel SA 相関 - 通貨/商品
Poxel SA 財務諸表
Annual | 2023 |
収益: | €1.98M |
総利益: | €1.98M (100.00 %) |
EPS: | €0 |
FY | 2023 |
収益: | €1.98M |
総利益: | €1.98M (100.00 %) |
EPS: | €0 |
FY | 2022 |
収益: | €674 000 |
総利益: | €2 000.00 (0.30 %) |
EPS: | €-1.080 |
FY | 2021 |
収益: | €13.40M |
総利益: | €13.34M (99.56 %) |
EPS: | €-0.830 |
Financial Reports:
No articles found.
Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。